Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (opens new window)

Abdelrazik N, Fouda M

Source‎: Hematology 2007;12(6):533-41.

Indexed‎: PubMed 17852440

DOI‎: 10.1080/10245330701521572

https://www.ncbi.nlm.nih.gov/pubmed/17852440 (opens new window)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (opens new window)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Source‎: Cancer 2012;118(3):848-55.

Indexed‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (opens new window)

Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (opens new window)

Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A

Source‎: Pediatr Hematol Oncol 2008;25(6):509-21.

Indexed‎: PubMed 18728970

DOI‎: 10.1080/08880010802235132

https://www.ncbi.nlm.nih.gov/pubmed/18728970 (opens new window)

Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (opens new window)

Durmaz O, Demirkaya M, Sevinir B

Source‎: Pediatr Hematol Oncol 2011;28(6):461-8.

Indexed‎: PubMed 21707225

DOI‎: 10.3109/08880018.2011.570857

https://www.ncbi.nlm.nih.gov/pubmed/21707225 (opens new window)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (opens new window)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Source‎: J Clin Oncol 2010;28(13):2239-45.

Indexed‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (opens new window)

Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (opens new window)

Hassan BA, Yusoff ZB

Source‎: Asian Pac J Cancer Prev 2011;12(6):1573-6.

Indexed‎: PubMed 22126501

https://www.ncbi.nlm.nih.gov/pubmed/22126501 (opens new window)

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (opens new window)

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group

Source‎: Curr Med Res Opin 2009;25(9):2109-20.

Indexed‎: PubMed 19601709

DOI‎: 10.1185/03007990903084164

https://www.ncbi.nlm.nih.gov/pubmed/19601709 (opens new window)

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (opens new window)

Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI

Source‎: J Support Oncol 2005;3(6 Suppl 4):10-1.

Indexed‎: PubMed 16355549

https://www.ncbi.nlm.nih.gov/pubmed/16355549 (opens new window)

The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (opens new window)

Hiradfar A, Banihosseinian M

Source‎: Iran J Ped Hematol Oncol 2014;4(4):151-9.

Indexed‎: PubMed 25598955

https://www.ncbi.nlm.nih.gov/pubmed/25598955 (opens new window)

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (opens new window)

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Source‎: Pediatr Blood Cancer 2009;53(1):7-12.

Indexed‎: PubMed 19229970

DOI‎: 10.1002/pbc.21953

https://www.ncbi.nlm.nih.gov/pubmed/19229970 (opens new window)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Source‎: Cancer 2013;119(1):107-14.

Indexed‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)

Erythropoietic growth factors for children with cancer: a systematic review of the literature. (opens new window)

Mystakidou K, Potamianou A, Tsilika E

Source‎: Curr Med Res Opin 2007;23(11):2841-7.

Indexed‎: PubMed 17910805

DOI‎: 10.1185/030079907x242601

https://www.ncbi.nlm.nih.gov/pubmed/17910805 (opens new window)

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (opens new window)

Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR

Source‎: J Clin Oncol 2006;24(22):3583-9.

Indexed‎: PubMed 16877725

DOI‎: 10.1200/JCO.2005.03.4371

https://www.ncbi.nlm.nih.gov/pubmed/16877725 (opens new window)

The role of recombinant erythropoietin in childhood cancer. (opens new window)

Shankar AG

Source‎: Oncologist 2008;13(2):157-66.

Indexed‎: PubMed 18305061

DOI‎: 10.1634/theoncologist.2007-0126

https://www.ncbi.nlm.nih.gov/pubmed/18305061 (opens new window)

Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (opens new window)

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, Piedra P, Saurez G, Verdecia M, Cabanas R

Source‎: MEDICC Rev 2010;12(3):27-31.

Indexed‎: PubMed 20697335

DOI‎: 10.37757/MR2010.V12.N3.7

https://www.ncbi.nlm.nih.gov/pubmed/20697335 (opens new window)

A single institutional experience: is epoetin alpha effective in anemic children with cancer? (opens new window)

Yilmaz D, Cetingül N, Kantar M, Oniz H, Kansoy S, Kavakli K

Source‎: Pediatr Hematol Oncol 2004;21(1):1-8.

Indexed‎: PubMed 14660300

https://www.ncbi.nlm.nih.gov/pubmed/14660300 (opens new window)

Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (opens new window)

Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, Wali Y

Source‎: Pediatr Hematol Oncol 2014;31(5):442-7.

Indexed‎: PubMed 24088186

DOI‎: 10.3109/08880018.2013.824527

https://www.ncbi.nlm.nih.gov/pubmed/24088186 (opens new window)

Early epoetin alfa treatment in children with solid tumors. (opens new window)

Zoubek A, Kronberger M

Source‎: Med Pediatr Oncol 2002;39(4):459-62.

Indexed‎: PubMed 12203664

DOI‎: 10.1002/mpo.10186

https://www.ncbi.nlm.nih.gov/pubmed/12203664 (opens new window)

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (opens new window)

Crary SE, Hall K, Buchanan GR.

Source‎: Pediatr Blood Cancer 2011;56(4):615-9.

Indexed‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

https://www.ncbi.nlm.nih.gov/pubmed/21298748 (opens new window)

Intravenous iron sucrose for children with iron deficiency anemia. (opens new window)

Kaneva K, Chow E, Rosenfield CG, Kelly MJ

Source‎: J Pediatr Hematol Oncol 2017;39(5):e259-62.

Indexed‎: PubMed 28562517

DOI‎: 10.1097/MPH.0000000000000879

https://www.ncbi.nlm.nih.gov/pubmed/28562517 (opens new window)

Advances in Pediatric Intravenous Iron Therapy. (opens new window)

Mantadakis E.

Source‎: Pediatr Blood Cancer 2016;63(1):11-6.

Indexed‎: PubMed 26376214

DOI‎: 10.1002/pbc.25752

https://www.ncbi.nlm.nih.gov/pubmed/26376214 (opens new window)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (opens new window)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Source‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indexed‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (opens new window)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (opens new window)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Source‎: J Clin Oncol 2008;26(10):1619-25.

Indexed‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (opens new window)

Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (opens new window)

Plummer ES, Crary SE, McCavit TL, Buchanan GR

Source‎: Pediatr Blood Cancer 2013;60(11):1747-52.

Indexed‎: PubMed 23832487

DOI‎: 10.1002/pbc.24676

https://www.ncbi.nlm.nih.gov/pubmed/23832487 (opens new window)